Efficacy of deoxycholate amphotericin B and unilamellar liposomal amphotericin B in prophylaxis of experimental Aspergillus fumigatus endocarditis

Mayo Clinic Proceedings

Volumn 72, Issue 11, 1997, Pages 1022-1027

  Mylonakis, Eleftherios ^a,d   Chalevelakis, George ^a   Saroglou, George ^a   Danias, Peter ^b   Argyropoulou, Athina D ^c   Paniara, Olga ^c   Raptis, Sotirios A ^d  

^a Second Department of Internal Medicine   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c First Internal Medicine Department

^d UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; LIPOSOME;

ANIMAL MODEL; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; BLOOD CULTURE; CONTROLLED STUDY; DRUG EFFICACY; ENDOCARDITIS; EXPERIMENTAL INFECTION; FUNGUS CULTURE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; RABBIT;

EID: 0030727212     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/72.11.1022     Document Type: Article

References (52)

1. Beyer J, Schwartz S, Heinemann V, Siegert W. Strategies in prevention of invasive pulmonary aspergillosis in immunosuppressed or neutropenic patients. Antimicrob Agents Chemother 1994;38:911-917
2. Myers SE, Devine SM, Topper RL, Ondrey M, Chandler C, O'Toole K, et al. A pilot study of prophylactic aerosolized amphotericin B in patients at risk for prolonged neutropenia. Leuk Lymphoma 1992;8:229-233
3. Walsh TJ, Lee JW. Prevention of invasive fungal infections in patients with neoplastic disease. Clin Infect Dis 1993;17(Suppl 2):S468-S480
4. Hertenstein B, Kern WV, Schmeiser T, Stefanie M, Bunjes D, Wiesneth M, et al. Low incidence of invasive fungal infections after bone marrow transplantation in patients receiving amphotericin B inhalations during neutropenia. Ann Hematol 1994;68:21-26
5. Rhame FS. Prevention of nosocomial aspergillosis. J Hosp Infect 1991;18(SupplA):466-472
6. Denning DW. Treatment of invasive aspergillosis. J Infect 1994;28(Suppl l):25-33
7. Espinel-Ingroff A, Pfaller MA. Antifungal agents and susceptibility testing. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, editors. Manual of Clinical Microbiology. 6th ed. Washington (DC): American Society for Microbiology; 1995. pp 1405-1414
8. Bodey GP, Anaissie EJ, Elting LS, Estey E, O'Brien S, Kantarjian H. Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. Cancer 1994;73:20992106
9. Rousey SR, Russler S, Gottlieb M, Ash RC. Low-dose amphotericin B prophylaxis against invasive Aspergillus infections in allogeneic marrow transplantation. Am J Med 1991;91:484-492
10. Tollemar J, Ringden O, Andersson S, Sundberg B, Ljungman P, Tyden G. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1993;12:577-582
11. Tollemar J, Hockerstedt K, Ericzon BG, Jalanko H, Ringden O. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients: a randomized, placebocontrolled study. Transplantation 1995;59:45-50
12. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis 1990;12:1147-1201
13. Andriole VT, Miniter P, George D, Kordick D, Patterson TF. Animal models: usefulness for studies of fungal pathogenesis and drug efficacy in aspergillosis. Clin Infect Dis 1992;14(Suppl 1):S134-S138
14. Allendoerfer R, Loebenberg D, Rinaldi MG, Graybill JR. Evaluation of SCH51048 in an experimental model of pulmonary aspergillosis. Antimicrob Agents Chemother 1995; 39:1345-1348
15. Graybill JR, Kaster SR, Drutz DJ. Treatment of experimental murine aspergillosis with Bay n7133. J Infect Dis 1983; 148:898-906
16. Carrizosa J, Kohn C, Levison ME. Experimental Aspergillus endocarditis in rabbits. J Lab Clin Med 1975;86:746-753
17. Longman LP, Martin MV. A comparison of the efficacy of itraconazole, amphotericin B and 5-fluorocytosine in the treatment of Aspergillus fumigatus endocarditis in the rabbit. J Antimicrob Chemother 1987;20:719-724
18. Witt MD, Bayer AS. Comparison of fluconazole and amphotericin B for prevention and treatment of experimental Candida endocarditis. Antimicrob Agents Chemother 1991; 35:2481-2485
19. Yeaman MR, Soldan SS, Ghannoum MA, Edwards JE Jr, Filler SG, Bayer AS. Resistance to platelet microbicidal protein results in increased severity of experimental Candida albicans endocarditis. Infect Immun 1996;64:1379-1384
20. Bayer AS, Witt MD, KimE, Ghannoum MA. Comparison of fluconazole and amphotericin B in prophylaxis of experimental Candida endocarditis caused by non-C. albicans strains. Antimicrob Agents Chemother 1996;40:494-496
21. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Proposed Standards. Villanova (PA): National Committee for Clinical Laboratory Standards; 1992 (Document M27-P)
22. DurackDT, Beeson PB, PetersdorfRG. Experimental bacterial endocarditis. III. Production and progress of the disease in rabbits. BrJExpPathol 1973;54:142-151
23. Lee JW, Amantea MA, Francis PA, Navarro EE, Bacher J, Pizzo PA, et al. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob Agents Chemother 1994;38:713718
24. Meunier F. New methods for delivery of antifungal agents. Rev Infect Dis 1989;ll(Suppl 7):S1605-S1612
25. Kaatz GW, Seo SM, Barriere SL, Albrecht LM, Rybak MJ. Development of resistance to fleroxacin during therapy of experimental methicillin-susceptible Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 1991 ;35:15471550
26. Chemlal K, Saint-Julien L, Joly V, Farinotti R, Seta N, Yeni P, et al. Comparison of fluconazole and amphotericin B for treatment of experimental Candida albicans endocarditis in rabbits. Antimicrob Agents Chemother 1996;40:263-266
27. George D, Kordick D, Miniter P, Patterson TF, Andriole VT. Combination therapy in experimental invasive aspergillosis. J Infect Dis 1993; 168:692-698
28. Kisch AL, Maydew RP, Evan AP. Synergistic nephrotoxicity of amphotericin B and cortisone acetate in mice. J Infect Dis 1978; 137:789-794
29. Wright AJ, Wilson WR. Experimental animal endocarditis. Mayo Clin Proc 1982;57:10-14
30. Bayer AS, Yih J, Chiu CY, Nast CC. Pathogenetic effects of monocytopenia, granulocytopenia and dexamethasone on the course of experimental Pseudomonas aeruginosa endocarditis in rabbits. Chemotherapy 1989;35(Suppl):278-288
31. Berney P, Francioli P. Successful prophylaxis of experimental streptococcal endocarditis with single-dose amoxicillin administered after bacterial challenge. J Infect Dis 1990; 161:281-285
32. De Bock R (EORTC Invasive Fungal Infections Cooperative Group). Epidemiology of invasive fungal infections in bone marrow transplantation. Bone Marrow Transplant 1994; 14(Suppl5):Sl-S2
33. Paya CV. Fungal infections in solid-organ transplantation. Clin Infect Dis 1993; 16:677-688
34. Georgopapadakou NH, Walsh TJ. Antifungal agents: chemotherapeutic targets and immunologie strategies. Antimicrob Agents Chemother 1996;40:279-291
35. Anaissie E. Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin Infect Dis 1992;14(Suppl 1):S43-S53
36. Opal SM, Asp AA, Cannady PB Jr, Morse PL, Burton LJ, Hammer PGII. Efficacy of infection control measures during a nosocomial outbreak of disseminated aspergillosis associated with hospital construction. J Infect Dis 1986; 153: 634-637
37. Pannuti CS, Gingrich RD, Pfaller MA, Wenzel RP. Nosocomial pneumonia in adult patients undergoing bone marrow transplantation: a 9-year study. J Clin Oncol 1991; 9:77-84
38. Sherertz RJ, Belani A, Kramer BS, Elfenbein GJ, Weiner RS, Sullivan ML, et al. Impact of air filtration on nosocomial Aspergillus infections: unique risk of bone marrow transplant recipients. Am J Med 1987;83:709718
39. Jeffrey GM, Beard ME, Ikram RB, Chua J, Alien JR, Heaton DC, et al. Intranasal amphotericin B reduces the frequency of invasive aspergillosis in neutropenic patients. Am J Med 1991:90:685-692
40. Beyer J, Schwartz S, Barzen G, Risse G, Dullenkopf K, Weyer C, et al. Use of amphotericin B aerosols for the prevention of pulmonary aspergillosis. Infection 1994; 22:143-148
41. Schmitt HJ. New methods of delivery of amphotericin B. Clin Infect Dis 1993;17(Suppl 2):S501-S506
42. Mills W, Chopra R, Linch DC, Goldstone AH. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. Br J Haematol 1994;86:754760
43. Ng TT, Denning DW. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections: evaluation of United Kingdom compassionate use data. Arch Intern Med 1995; 155:1093-1098
44. Clements JS Jr, Peacock JE Jr. Amphotericin B revisited: reassessment of toxicity. Am J Med 1990;88(Suppl 5N): 22N-27N
45. Norris SM. Amphotericin-how safe and effective? Infect Control 1985;6:243-245
46. Cruz JM, Peacock JE Jr, Loomer L, Holder LW, Evans GW, Powell BL, et al. Rapid intravenous infusion of amphotericin B: a pilot study. Am J Med 1992;93:123130
47. Adler-Moore J. AmBisome targeted to fungal infections. Bone Marrow Transplant 1994;14(Suppl 5):S3-S7
48. Perfect JR, Klotman ME, Gilbert CC, Crawford DD, Rosner GL, Wright K A, et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 1992;165:891-897
49. Singh N, Mieles L, Yu VL, Gayowski T. Invasive aspergillosis in liver transplant recipients: association with candidemia and consumption coagulopathy and failure of prophylaxis with low-dose amphotericin B. Clin Infect Dis 1993; 17:906-908
50. Hay RJ. The role of chemoprophylaxis in the prevention of airborne infection by fungal pathogens. J Hosp Infect 1991;18(SupplA):460-465
51. Hay RJ. The prevention of invasive aspergillosis-a realistic goal? J Antimicrob Chemother 1993;32:515-517
52. Momin F, Chandrasekar PH. Antimicrobial prophylaxis in bone marrow transplantation. Ann Intern Med 1995; 123:205-215